Welcome to our dedicated page for Genprex news (Ticker: GNPX), a resource for investors and traders seeking the latest updates and insights on Genprex stock.
Genprex, Inc. (NASDAQ: GNPX) is a pioneering clinical-stage gene therapy company committed to transforming the landscape of cancer and diabetes treatments. The company's mission is to address the unmet medical needs of a growing population of patients worldwide through the development of innovative immunogene therapies. Genprex's flagship product, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is at the forefront of its oncology program and is currently being evaluated in three clinical trials targeting non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).
Oncoprex® Delivery System, Genprex's proprietary platform, encapsulates gene-expressing plasmids using lipid-based nanoparticles. This systemic, non-viral method enables the intravenous delivery of tumor suppressor genes to cancer cells, which then express proteins that were deficient in the tumor. Reqorsa Immunogene Therapy has shown promise by re-establishing pathways for programmed cell death, interrupting cancer cell signaling, and modulating immune responses.
The company's recent achievements include securing new patents and receiving FDA Fast Track and Orphan Drug designations for its clinical programs. Specifically, the Acclaim-2 and Acclaim-3 studies are exploring the potential of Reqorsa in combination with immune checkpoint inhibitors like Keytruda® and Tecentriq®. These trials aim to provide new therapeutic options for patients with advanced-stage lung cancers who have limited treatment alternatives.
In addition to its oncology initiatives, Genprex is advancing a novel gene therapy approach for diabetes. Using an AAV vector, the company delivers Pdx1 and MafA genes directly to the pancreas to transform alpha cells into beta-like cells capable of producing insulin. This method shows promise for both Type 1 and Type 2 diabetes and aims to offer a new lifeline for patients with these conditions.
Genprex collaborates with renowned institutions and industry leaders to further its research and development pipeline. The company's commitment to innovation and patient-centric solutions positions it as a significant player in the gene therapy landscape.
Latest News:
- March 12, 2024 - Genprex announces new patent grants in South Korea for Reqorsa® Immunogene Therapy.
- March 19, 2024 - Genprex enters into agreements for the sale and issuance of shares, expecting gross proceeds of $6.5 million.
- April 2, 2024 - Positive preclinical data for NPRL2 gene therapy presented at AACR Annual Meeting.
- April 3, 2024 - Multiple new trial sites added for Acclaim-3 study in extensive-stage small cell lung cancer.
- April 9, 2024 - Research collaborators present positive preclinical data supporting Reqorsa and NPRL2 therapies.
- May 8, 2024 - Genprex announces the passing of its co-founder and CEO Rodney Varner.
- May 14, 2024 - First patient dosed in Phase 1 of Acclaim-3 clinical study for Reqorsa® and Tecentriq® combination therapy.
Genprex, Inc. (Nasdaq: GNPX) has entered into a securities purchase agreement with a healthcare-dedicated institutional investor to sell 3,116,884 shares of its common stock at $3.85 per share. This registered direct offering is priced at-the-market under Nasdaq rules, with no warrants issued. The closing is expected around December 24, 2020, subject to customary conditions. A.G.P./Alliance Global Partners acts as the sole placement agent. The offering is made under an effective shelf registration statement previously filed with the SEC.
Genprex, Inc. (GNPX) has completed the manufacturing scale-up of REQORSA™ immunogene therapy, aimed at supplying the Acclaim-1 and Acclaim-2 clinical trials for non-small cell lung cancer. This production adheres to current Good Manufacturing Practices (cGMP) and includes significant advancements that enhance yield and reduce costs. Upon passing final testing, REQORSA will be stored at controlled temperatures before distribution. These trials will assess REQORSA in combination with AstraZeneca's Tagrisso® and Merck's Keytruda® in early 2021, potentially impacting the $26.3 billion lung cancer therapeutics market.
Genprex, Inc. (NASDAQ: GNPX) announced the successful completion of the technology transfer for its lead drug candidate, REQORSA™. This achievement signifies the first commercial-scale production in a cGMP-compliant facility, previously conducted at a major cancer research institution. The company expects enhanced production reliability and scalability, crucial for their upcoming Acclaim-1 and Acclaim-2 clinical trials involving combinations of REQORSA with Tagrisso® and Keytruda®. This milestone represents a significant step forward in Genprex’s drug development efforts.
Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company, will present at the Benzinga Global Small Cap Conference on December 8. CEO Rodney Varner will provide insights on recent advancements in the Acclaim-1 clinical trial. The virtual event aims to connect small-cap companies with investors, offering opportunities for one-on-one engagement. Genprex focuses on developing innovative therapies for cancer and diabetes, particularly through its lead product, REQORSA™, which targets non-small cell lung cancer. Registration for the conference is available online.
Genprex, Inc. (NASDAQ: GNPX) has begun recruitment for its Acclaim-1 clinical trial targeting non-small cell lung cancer (NSCLC). This Phase 1/2 trial will assess the efficacy of REQORSA™ immunogene therapy combined with AstraZeneca's Tagrisso in late-stage NSCLC patients with EGFR mutations. The trial plans to enroll approximately 100 patients across 10 U.S. sites, with an interim analysis after 53 events. Genprex received FDA Fast Track Designation for this trial, enhancing its market potential.
Genprex, Inc. (NASDAQ: GNPX) announced its participation in the Diamond Equity Research Emerging Growth Invitational, set for December 1, 2020, at 11:40 a.m. EST. Executive Vice President Michael Redman will present a company overview and engage in a Q&A session. The virtual event aims to showcase Genprex's advancements in gene therapies for cancer and diabetes. The company's leading drug candidate, REQORSA™, is in development for non-small cell lung cancer and has received Fast Track Designation from the FDA. More details can be found on Genprex's website.
Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company, announced that Thomas Gallagher, Senior VP of Intellectual Property and Licensing, will join a panel at the virtual Life Sciences Summit on November 17-18, 2020. The panel, titled “Show Me the Money: Preparing Your Company for Funding,” aims to guide emerging companies in securing funding. Key topics will include intellectual property strategy, due diligence, and investor relations. The Life Sciences Summit connects early-stage investors with innovative companies and academic professionals to advance clinical developments.
Genprex, Inc. (NASDAQ: GNPX) has appointed Dr. George K. Gittes to its Scientific Advisory Board. Dr. Gittes is recognized for his work on the company's diabetes gene therapy technology, which has the potential to provide a cure for diabetes, affecting over 30 million people in the U.S. This addition is expected to enhance Genprex’s strategy as it advances its diabetes clinical development program. Rodney Varner, President and CEO of Genprex, noted the importance of Dr. Gittes' expertise in driving the company's efforts to benefit patients with diabetes.
Genprex, Inc. (NASDAQ: GNPX) announced the launch of new branding for its upcoming oncology clinical trials combining its lead drug candidate, REQORSA™ (quaratusugene ozeplasmid), with AstraZeneca’s Tagrisso® (osimertinib) and Merck’s Keytruda® (pembrolizumab) for non-small cell lung cancer (NSCLC). The trials, branded as 'Acclaim,' aim to provide hope for NSCLC patients. Acclaim-1 targets late-stage NSCLC with mutated EGFRs, while Acclaim-2 targets low expressors of PD-L1. The trials are expected to commence in the first half of 2021.
Genprex, Inc. (NASDAQ: GNPX) announced that the FDA has conditionally accepted the proprietary name REQORSA™ for its lead drug candidate targeting non-small cell lung cancer, previously known as GPX-001. This name approval is a critical step towards marketing the therapy and enhances the brand identity of Genprex. The REQORSA drug utilizes the ONCOPREX® nanoparticle delivery system and previously received Fast Track Designation from the FDA. Final approval of the name is contingent upon successful clinical trials and FDA product candidate approval.
FAQ
What is the current stock price of Genprex (GNPX)?
What is the market cap of Genprex (GNPX)?
What is Genprex's main focus?
What is Reqorsa Immunogene Therapy?
How does the Oncoprex® Delivery System work?
What recent achievements has Genprex made?
What is the status of Genprex's clinical trials?
What are the implications of Genprex's recent patent grants?
What is Genprex's approach to diabetes treatment?
How does Reqorsa enhance current cancer treatments?
Who are Genprex's key collaborators?
How has Genprex adapted to recent leadership changes?
